Phaseline

Companies › Simcha IL-18

Simcha IL-18: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ST-067
Engineered variant of human interleukin-18
IL18Phase 1Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04787042ST-067Phase 1CancerOncologyJun 2025

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

IL18 (1)

Companies with the same targets

Apollo Therapeutics GSK

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.